Drug Improves Muscle Function and Survival in Spinal Muscular Atrophy

Final results from a phase 3 clinical trial of nusinersen (Spinraza) published in NEJM

Article ID: 684674

Released: 6-Nov-2017 2:05 PM EST

Source Newsroom: Ann & Robert H. Lurie Children's Hospital of Chicago

  • Nancy Kuntz, MD, Lurie Children's

Newswise — More than half of the babies with infantile-onset spinal muscular atrophy (SMA) who were treated with nusinersen (Spinraza) gained motor milestones, compared to none of the babies in the control group. Infants treated with the drug also had 63 percent lower risk of death. These final results from the 13-month, international, randomized, multicenter, sham procedure-controlled, phase 3 trial called ENDEAR were published in the New England Journal of Medicine.

          Babies born with SMA, a genetic disorder affecting nerves that control muscle movement, cannot hold up their heads, roll over or sit up independently. They often do not survive beyond 2 years of age.

          “This landmark study provides the most robust type of evidence that nusinersen, which targets the genetic defect in SMA, can safely and effectively help infants with this devastating condition gain muscle function,” said study co-author Nancy Kuntz, MD, Principal Investigator at Ann & Robert H. Lurie Children’s Hospital of Chicago, Medical Director of Mazza Foundation Neuromuscular Program and Professor of Pediatrics and Neurology at Northwestern University Feinberg School of Medicine.

          Nusinersen was the first drug for SMA to receive approval by the U.S. Food and Drug Administration (FDA) after an interim analysis of the ENDEAR trial showed positive results.

          Due to a genetic defect, infants with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the maintenance of motor nerve cells. Nusinersen is designed to increase production of fully functional SMN protein by regulating gene expression. The drug is administered by injection into the spinal fluid. Repeated doses are needed.

          “While we saw exciting improvements in babies with SMA, our findings also show that nusinersen is not a cure,” said Kuntz. “None of the infants treated with the drug achieved normal motor development and some did not survive. Others, despite treatment, still needed support with feeding and breathing. We observed, however, that starting treatment earlier maximizes the benefit of the drug.”

          The study was supported by Biogen and Ionis Pharmaceuticals.

Research at Ann & Robert H. Lurie Children’s Hospital of Chicago is conducted through the Stanley Manne Children’s Research Institute. The Manne Research Institute is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children’s is ranked as one of the nation’s top children’s hospitals in the U.S.News & World Report. It is the pediatric training ground for Northwestern University Feinberg School of Medicine. Last year, the hospital served more than 208,000 children from 50 states and 58 countries.

SEE ORIGINAL STUDY


Comment/Share





Chat now!